Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Cipla
Medtronic
AstraZeneca
Queensland Health
UBS
Julphar
Dow
Boehringer Ingelheim
Citi

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: RE35724

« Back to Dashboard

Summary for Patent: RE35724
Title: Contraception system and method
Abstract:A method of contraception is disclosed which comprises a two-stage protocol. In the first stage, an estrogenic compound in a first composition is administered daily as the sole contraceptively active substance to a human female from about Day 2 to about Day 7 of her menstrual cycle, where Day 1 is the first day of menses. The second stage of the protocol occurs immediately thereafter during which at least one follow-up composition containing a progestin is administered daily to the same human female. The follow-up composition can contain a progestin as the sole contraceptively active ingredient, or can contain a combination of an estrogenic compound with a progestin in different weight ratios. A drug delivery system containing daily dosage units is also described.
Inventor(s): Pasquale; Samuel A. (Basking Ridge, NJ)
Assignee: Bio-Technology General Corp. (Iselin, NJ)
Application Number:08/369,309
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Delivery; Compound;

Drugs Protected by US Patent RE35724

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent RE35724

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 175353 ➤ Sign Up
Australia 4497089 ➤ Sign Up
Australia 620940 ➤ Sign Up
Canada 2001144 ➤ Sign Up
Germany 68928897 ➤ Sign Up
European Patent Office 0397823 ➤ Sign Up
Finland 103951 ➤ Sign Up
Hungary 211931 ➤ Sign Up
Hungary T51899 ➤ Sign Up
Israel 92069 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Johnson and Johnson
Moodys
Cerilliant
Mallinckrodt
Argus Health
Boehringer Ingelheim
Citi
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot